1) 阿部達生:二次白血病, therapy-linked leukemiaの臨床と病因に関する考察. 京府医大誌92:1-15, 1983
2) 阿部達生, 瀧野辰郎:化学物質と染色体異常. 腫瘍染色体アトラス, 阿部達生, 鎌田七男, 桜井雅温編, 南江堂, 東京, 1986, pp. 85-95
3) Abe, T., Tsuda, S., Maekawa, T. et al.:Sister chromatid exchanges induced by cancer chemotherapeutic drugs in vitro and in vivo:consideration of the hazard of drugs as possible mutagens and carcinogens. Cancer Treat. Rep. 69:505-514, 1985
4) Hunger, S. P., Kaminer, L. S., Bitran, J. D. et al.:HRX involvement in de novo and secondaryleukemias with diverse chromosome 11q23 abnormalities. Blood 81:3197-3203, 1993
5) Gill Super, H. J., McCabe, N. R, Thirman, M. L. et al:Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targetting DNA-topoisomerase II. Blood 82:3706-3711, 1993
6) Ratain, M. J., Tkachuk, D. C., Amylon, M. D. et al.:Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung. Blood 70:1412-1417, 1987
7) Pedersen-Bjergaard, J., Philip, P., Larsen, S. O. et al.:Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7:1975-1986, 1993
8) Wolff, S.:Chromosome aberrations, sister chromatid exchanges, and the lesions that produce them. In:Sister Chromatid Exchange, ed. by Wolff, S., John:Wiley &Sons, NY, 1982, pp. 41-57
9) 0be, G. and Natarajan, A. T.:Mechanism of the origin of structural chromosomal aberrations. In:Sister-Chromatid Exchange Test, ed. by Mueller, D. et al., Georg Thieme Verlag, Stuttgart, 1982, pp. 1-5
10) 阿部達生:多型と日常の病気. 遺伝子と日常の病気, 医学書院, 東京, 1994, pp. 181-211
11) Davies, S. M.:Mechanisms of cytotoxicity and leukemogenesis:topoisomerase II inhibitors and alkylating agents. In:ASCO 31, Ann Meet, 1995, pp. 204-206
12) 中別府雄作:突然変異制御機構の異常と発癌. 医学のあゆみ171:414-420, 1994
13) Greenblatt, M. S., Bennett, W. P., Hollstein, M. et al.:Mutations in the p 53 tumor suppressor gene:clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878, 1994
15) 阿部達生, 稲澤譲治, 谷脇雅史:染色体異常. 臨床腫瘍学, 有吉寛ほか編, 癌と化学療法社, 東京, 1996, pp. 109-130
16) 安藤俊夫:DNAトポイソメラーゼ阻害剤. 医薬ジャーナル30:99-104, 1994
17) 今本文男:DNAはどのように折り畳まれて働くか. 共立出版, 東京, 1995
18) 菊池詔彦:DNAの冒険-二重らせんから超らせんへ. 岩波書店, 東京, 1993
20) Wolffe, A.:Chromatin Strncure & Function. 2nd ed. Academic Press, San Diego, 1995
23) Strissel Broeker, P. L., Gil Super, H., Thirman, M. J. et al.:Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia:correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87:1912-1922, 1996
25) 石川冬木:ゲノムクライシス-何が腫瘍を引き起こすか. 化学と生物33:635-644, 1995